Home flu vaccination can be delivered in 34 states across the country
For the upcoming 2025-26 flu season, AstraZeneca's FluMist, a nasal-spray flu vaccine, will be available for home use. This innovative offering aims to increase convenience and potentially boost flu vaccination rates by providing a needle-free alternative.
Ordering FluMist at Home
To avail of this at-home option, ensure you are eligible. FluMist is approved for at-home use for individuals aged between 2 to 49. Children aged 2-17 require caregiver administration, while adults aged 18-49 can self-administer.
Before placing your order, confirm that FluMist Home delivery is available in your state. For the 2025-26 flu season, FluMist Home will not be available in several states due to local pharmacy laws, including Alaska, Arkansas, Washington D.C., Delaware, Hawaii, Indiana, and a few others.
Once you've confirmed your eligibility and availability, visit the designated online ordering platform for FluMist Home. You will need to provide basic personal information, medical details, insurance information, and a payment method for shipping and handling (approximately $8.99 for shipping and processing). Most commercial insurance plans cover the cost of FluMist, so you may not need to pay for the vaccine itself.
Using FluMist at Home
Follow the instructions provided by the website or the packaging for administering the vaccine. For children, a caregiver should administer the vaccine, while adults can self-administer. Ensure you are not allergic to any components of FluMist, including eggs or other flu vaccines.
Keep the vaccine refrigerated at the recommended temperature to ensure potency until use. After administration, monitor for any adverse reactions and contact a healthcare provider if necessary.
A New Era in Healthcare Delivery
FluMist Home marks a historic shift in how preventive care is delivered, offering a seamless, end-to-end experience. This new model of care puts consumers in control and sets the stage for a more accessible, patient-centered future in healthcare.
Joris Silon, US Country President and Senior Vice President of AstraZeneca, stated that the launch of FluMist Home marks a significant moment in the evolution of influenza protection. FluMist Home is part of AstraZeneca's commitment to continuous innovation and making it easier for people to get vaccinated and stay protected.
For the 2025-26 flu season, FluMist Home is rolling out to 34 states, covering about 80% of eligible people. AstraZeneca aims to expand to all 48 contiguous states in future flu seasons.
Remember, consumers should always check with their healthcare providers before ordering and administering FLUMIST. Kids aged 2-17 can receive a dose from a parent or caregiver at home. The vaccine is covered by insurance for eligible individuals.
FLUMIST is the only nasal-spray flu vaccine approved in the U.S. Traditional clinic- and pharmacy-administered FLUMIST is also available nationwide.
[1] AstraZeneca Press Release, FluMist Home Now Available for At-Home Use during the 2025-26 Flu Season, www.astrazeneca.com/news/press-releases
[2] FluMist Home User Guide, www.FluMist.com/user-guide
[3] Centers for Disease Control and Prevention, FluMist Home Availability, www.cdc.gov/flu/vaccines-work/vaccines/nasal-spray.htm
- The availability of FluMist Home, a nasal-spray flu vaccine for at-home use, not only boosts convenience for the upcoming 2025-26 flu season but also aligns with the health-and-wellness trend, allowing consumers to take control of their preventive care.
- For eligible individuals, the science behind FluMist, a needle-free alternative, combined with the health-and-wellness benefit of at-home administration, presents a promising approach towards improving vaccination rates and shaping the future of healthcare delivery.
